Literature DB >> 22773387

Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis.

M Kristen Demoruelle1, Kevin D Deane.   

Abstract

Data now suggest that current strategies in the treatment of rheumatoid arthritis (RA) should focus on early identification and diagnosis, followed by early initiation of DMARD therapy. Initiation of treatment in early RA-ideally, less than 3-6 months after symptom onset-improves the success of achieving disease remission and reduces joint damage and disability. While the optimal treatment regimen in early RA is unclear, use of initial DMARD mono- or combination therapy with prompt escalation to achieve low disease activity or remission is an appropriate approach. Ultimately, the goal of RA management should be the prevention of inflammatory joint disease and, thereby, prevention of disability. To date, studies have shown that pharmacologic interventions can delay progression from undifferentiated inflammatory arthritis to classifiable RA. However, further investigation is needed to identify asymptomatic individuals at high risk for future RA and to intervene early enough in the pathogenesis of RA to prevent progression to clinical disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22773387      PMCID: PMC3616381          DOI: 10.1007/s11926-012-0275-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  46 in total

1.  In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.

Authors:  Hamed Rezaei; Saedis Saevarsdottir; Kristina Forslind; Kristina Albertsson; Helena Wallin; Johan Bratt; Sofia Ernestam; Pierre Geborek; Ingemar F Pettersson; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2011-09-19       Impact factor: 19.103

2.  Long-term impact of delay in assessment of patients with early arthritis.

Authors:  Michael P M van der Linden; Saskia le Cessie; Karim Raza; Diane van der Woude; Rachel Knevel; Tom W J Huizinga; Annette H M van der Helm-van Mil
Journal:  Arthritis Rheum       Date:  2010-12

3.  Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort.

Authors:  Mohammed Z Cader; Andrew Filer; Jonathan Hazlehurst; Paola de Pablo; Christopher D Buckley; Karim Raza
Journal:  Ann Rheum Dis       Date:  2011-02-01       Impact factor: 19.103

Review 4.  Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis?

Authors:  Caroline Ospelt; Kris A Reedquist; Steffen Gay; Paul P Tak
Journal:  Autoimmun Rev       Date:  2011-04-09       Impact factor: 9.754

Review 5.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

6.  The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner.

Authors:  Kevin D Deane; Colin I O'Donnell; Wolfgang Hueber; Darcy S Majka; Ann A Lazar; Lezlie A Derber; William R Gilliland; Jess D Edison; Jill M Norris; William H Robinson; V Michael Holers
Journal:  Arthritis Rheum       Date:  2010-11

Review 7.  The value of early intervention in RA--a window of opportunity.

Authors:  Ferdinand Breedveld
Journal:  Clin Rheumatol       Date:  2011-02-25       Impact factor: 2.980

8.  Delays in assessment of patients with rheumatoid arthritis: variations across Europe.

Authors:  Karim Raza; Rebecca Stack; Kanta Kumar; Andrew Filer; Jacqueline Detert; Hans Bastian; Gerd R Burmester; Prodromos Sidiropoulos; Eleni Kteniadaki; Argyro Repa; Tore Saxne; Carl Turesson; Herman Mann; Jiri Vencovsky; Anca Catrina; Aikaterini Chatzidionysiou; Aase Hensvold; Solbritt Rantapää-Dahlqvist; Alexa Binder; Klaus Machold; Brygida Kwiatkowska; Adrian Ciurea; Giorgio Tamborrini; Diego Kyburz; Christopher D Buckley
Journal:  Ann Rheum Dis       Date:  2011-08-07       Impact factor: 19.103

9.  Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

Authors:  Saedis Saevarsdottir; Helena Wallin; Maria Seddighzadeh; Sofia Ernestam; Pierre Geborek; Ingemar F Petersson; Johan Bratt; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2010-12-13       Impact factor: 19.103

Review 10.  The need to better classify and diagnose early and very early rheumatoid arthritis.

Authors:  Henning Zeidler
Journal:  J Rheumatol       Date:  2011-12-15       Impact factor: 4.666

View more
  27 in total

1.  Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography.

Authors:  G Peluso; S L Bosello; E Gremese; L Mirone; F Di Gregorio; V Di Molfetta; T Pirronti; G Ferraccioli
Journal:  Clin Rheumatol       Date:  2015-04-23       Impact factor: 2.980

Review 2.  Targeting mechanisms at sites of complement activation for imaging and therapy.

Authors:  V Michael Holers
Journal:  Immunobiology       Date:  2015-04-30       Impact factor: 3.144

3.  Switching therapies in multiple sclerosis.

Authors:  Patricia K Coyle
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 4.  Targeting very early systemic sclerosis: a case-based review.

Authors:  Konstantinos Melissaropoulos; Pantelis Kraniotis; Dimitrios Bogdanos; Theodoros Dimitroulas; Lazaros Sakkas; Dimitrios Daoussis
Journal:  Rheumatol Int       Date:  2019-06-28       Impact factor: 2.631

Review 5.  Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis.

Authors:  V Michael Holers
Journal:  Curr Opin Immunol       Date:  2013-11-08       Impact factor: 7.486

6.  Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease.

Authors:  M Kristen Demoruelle; Mark C Parish; Lezlie A Derber; Jason R Kolfenbach; Jan M Hughes-Austin; Michael H Weisman; William Gilliland; Jess D Edison; Jane H Buckner; Ted R Mikuls; James R O'Dell; Richard M Keating; Peter K Gregersen; Jill M Norris; V Michael Holers; Kevin D Deane
Journal:  Arthritis Rheum       Date:  2013-09

7.  Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.

Authors:  Anand N Malaviya; S B Gogia
Journal:  Clin Rheumatol       Date:  2016-04-28       Impact factor: 2.980

Review 8.  Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.

Authors:  Kevin D Deane; Hani El-Gabalawy
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

9.  System A amino acid transporters regulate glutamine uptake and attenuate antibody-mediated arthritis.

Authors:  Bruno Raposo; Daniëlle Vaartjes; Emma Ahlqvist; Kutty-Selva Nandakumar; Rikard Holmdahl
Journal:  Immunology       Date:  2015-10-05       Impact factor: 7.397

Review 10.  Lipid and Metabolic Changes in Rheumatoid Arthritis.

Authors:  Catherine M McGrath; Stephen P Young
Journal:  Curr Rheumatol Rep       Date:  2015-09       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.